Glucuronate

Glucuronate

SCHEMBL22749019

O=C(O)[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDUA P35475 1/20 0.50
SUCNR1 Q9BXA5 1/20 0.48
FGF2 P09038 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
AKT1 P31749 1/20 0.33
HIF1A Q16665 1/20 0.31
AHCY P23526 1/20 0.31
TMEM97 Q5BJF2 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
GLA P06280 1/20 0.31
HPGD P15428 1/20 0.31
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.31
GBA1 P04062 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glucuronate SCHEMBL13324585 1.00 IDUA (0.50) IDUASUCNR1FGF2KDM4EALDH1A1
Glucuronate SCHEMBL15596891 1.00 IDUA (0.50) IDUASUCNR1FGF2KDM4EALDH1A1
Glucuronate SCHEMBL15177391 1.00 IDUA (0.50) IDUASUCNR1FGF2KDM4EALDH1A1
Glucuronate SCHEMBL20094857 1.00 IDUA (0.50) IDUASUCNR1FGF2KDM4EALDH1A1
Glucuronate SCHEMBL13376995 1.00 IDUA (0.50) IDUASUCNR1FGF2KDM4EALDH1A1
Glucuronate SCHEMBL6404275 1.00 IDUA (0.50) IDUASUCNR1FGF2KDM4EALDH1A1
Glucuronate SCHEMBL25253417 1.00 IDUA (0.50) IDUASUCNR1FGF2KDM4EALDH1A1
Glucuronate SCHEMBL21792734 1.00 IDUA (0.50) IDUASUCNR1FGF2KDM4EALDH1A1
Glucuronate SCHEMBL21312643 1.00 IDUA (0.50) IDUASUCNR1FGF2KDM4EALDH1A1
Glucuronate SCHEMBL6514487 1.00 IDUA (0.50) IDUASUCNR1FGF2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO claimed
US-11884961-B2 DNA-glycan conjugates and methods of use GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2024-01-30 US claimed
CN-116626664-A Radar shielding angle drawing method and device 北京华如科技股份有限公司 2023-08-22 CN claimed
US-20260107172-A1 METHOD, DEVICE AND COMPUTER STORAGE MEDIUM OF COMMUNICATION NEC CORPORATION (JP) 2026-04-16 US disclosed
EP-4668609-A1 DEVICE AND METHOD FOR REPORTING CHANNEL STATE INFORMATION ON BASIS OF SUB-CONFIGURATIONS IN WIRELESS COMMUNICATION SYSTEM LG Electronics Inc. (KR) 2025-12-24 EP disclosed
US-20250361477-A1 PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL INBIOSE NV (BE) 2025-11-27 US disclosed
EP-4608849-A1 SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE Inbiose N.V. (BE) 2025-09-03 EP disclosed
US-20250188504-A1 PRODUCTION OF A MIXTURE OF MAMMALIAN MILK OLIGOSACCHARIDES BY A CELL INBIOSE N.V. (BE) 2025-06-12 US disclosed
US-20250188503-A1 SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES INBIOSE N.V. (BE) 2025-06-12 US disclosed
WO-2025093666-A1 TREATMENT OF LYMPHOMA UNIVERSITY OF COPENHAGEN (DK) 2025-05-08 WO disclosed
CN-114503449-B Method and apparatus for multiplexing partial channel state information 三星电子株式会社 2025-04-18 CN disclosed
WO-2022034079-A2 PROCESS FOR PURIFICATION OF AN OLIGOSACCHARIDE SOLUTION PRODUCED BY CELL CULTIVATION OR MICROBIAL FERMENTATION INBIOSE N.V. (BE) 2022-02-17 WO disclosed
WO-2022034068-A1 PRODUCTION OF A MIXTURE OF MAMMALIAN MILK OLIGOSACCHARIDES BY A CELL INBIOSE N.V. (BE) 2022-02-17 WO disclosed
EP-3954769-A1 PRODUCTION OF OLIGOSACCHARIDE MIXTURES BY A CELL Inbiose N.V. (BE) 2022-02-16 EP disclosed
WO-2021160830-A1 GLYCOMINIMIZED BACTERIAL HOST CELLS INBIOSE N.V. (BE) 2021-08-19 WO disclosed
WO-2021160828-A1 KDO-FREE PRODUCTION HOSTS FOR OLIGOSACCHARIDE SYNTHESIS INBIOSE N.V. (BE) 2021-08-19 WO disclosed
WO-2021160829-A1 VIABLE BACTERIAL HOST CELL INBIOSE N.V. (BE) 2021-08-19 WO disclosed
WO-2021160827-A2 PRODUCTION OF GLYCOSYLATED PRODUCT IN HOST CELLS INBIOSE N.V. (BE) 2021-08-19 WO disclosed
WO-2021074182-A1 PRODUCTION OF BIOPRODUCT IN A HOST CELL INBIOSE N.V. (BE) 2021-04-22 WO disclosed
WO-2020245320-A1 OPTIMAL CHROMOSOMAL INSERTION LOCI INBIOSE N.V. (BE) 2020-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260107172-A1 METHOD, DEVICE AND COMPUTER STORAGE MEDIUM OF COMMUNICATION TNNC1, TMCO1, DSP IDUA 2383/4885SUCNR1 4672/4885FGF2 4096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.